Targeted protein degradation, or TPD, is a new and disruptive therapeutic approach for development of medicines. TPD utilizes the design of small molecules that can address disease-causing proteins that are highly challenging to drug. We discuss with @Alessio Ciulli about his exceptional career path as well as about the transformative potential of so-called PROTACs for TPD.

Alessio Ciulli studied chemistry at the University of Florence in Italy and completed his PhD at the University of Cambridge, UK. Early on Alessio worked with biophysical and structural analysis of protein-ligand interactions as well as fragment-based drug discovery. Alessio collaborated during his career with Chris Abell, Tom Blundell, and Craig Crews. Today, Alessio Ciulli is a full professor at the @University of Dundee as well as the Director of the new Centre for Targeted Protein Degradation

Alessio co-founded the biotech company @Amphista Therapeutics. The company is focused on developing therapeutics leading targeted protein degradation.